

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1: Name and Address of Reporting Issuer

Doseology Sciences Inc. (the “Company”)
Suite 305, 9–3151 Lakeshore Rd.
Kelowna, BC V1W 3S9

Item 2: Date of Material Change

February 16, 2024.

Item 3: News Release

A news release was issued and disseminated February 14, 2024 and filed on SEDAR+ at www.sedarplus.ca.

Item 4: Summary of Material Changes

The Company announced the effective date of its share consolidation. See item 5 for further details.

Item 5: Full Description of Material Change

The Company announced that the consolidation of its issued and outstanding common shares on the basis of ten (10) existing common shares for one (1) new common share of the Company took effect at market open on Friday, February 16, 2024 (the “Consolidation”), and, on that date, the Company’s common shares commenced trading on the Canadian Securities Exchange on a post-Consolidation basis.

On a pre-Consolidation basis, the Company had 44,005,250 common shares issued and outstanding, and, following the Consolidation, the Company has 4,400,515 post-Consolidation shares issued and outstanding, subject to rounding.

No fractional shares were issued pursuant to the Consolidation. Any fractional shares will be rounded down to the nearest whole number of common shares. No cash consideration will be paid in respect of fractional shares.

The CUSIP number for its post-Consolidation common shares is 258484203 and ISIN is CA2584842033.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

Not applicable.

Item 8: Executive Officer

For further information, please contact:

Shawn Balaghi, Interim CEO
Investor Relations: investor@doseology.com
General Inquiries: hello@doseology.com
Telephone: +1 825-800-0115

Item 9: Date of Report

February 16, 2024.